{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["16"],"submitter":["Ismail FS"],"pubmed_abstract":["Implications of glia in the pathophysiology of epilepsy raise the question of how these cells besides neurons are responsive to antiseizure medications (ASMs). Understanding ASM effects on glia and glia-mediated inflammation may help to explore astrocytes and microglia as potential targets for alternative anti-epileptogenic therapies. The aim of this study was to investigate the effects of the new generation ASM brivaracetam (BRV) in an astrocyte-microglia co-culture model of inflammation. Primary rat astrocytes co-cultures containing 5%-10% (M5, \"physiological\" conditions) or 30%-40% (M30, \"pathological inflammatory\" conditions) of microglia were treated with different concentrations of BRV (0.5, 2, 10, and 20 μg/ml) for 24 h. Glial cell viability was measured by MTT assay. Microglial act"],"journal":["Frontiers in cellular neuroscience"],"pagination":["995861"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9670320"],"repository":["biostudies-literature"],"pubmed_title":["Brivaracetam exhibits mild pro-inflammatory features in an <i>in vitro</i> astrocyte-microglia co-culture model of inflammation."],"pmcid":["PMC9670320"],"pubmed_authors":["Kummel ML","Faustmann PM","Forster E","Faustmann TJ","Corvace F","Ismail FS"],"additional_accession":[]},"is_claimable":false,"name":"Brivaracetam exhibits mild pro-inflammatory features in an <i>in vitro</i> astrocyte-microglia co-culture model of inflammation.","description":"Implications of glia in the pathophysiology of epilepsy raise the question of how these cells besides neurons are responsive to antiseizure medications (ASMs). Understanding ASM effects on glia and glia-mediated inflammation may help to explore astrocytes and microglia as potential targets for alternative anti-epileptogenic therapies. The aim of this study was to investigate the effects of the new generation ASM brivaracetam (BRV) in an astrocyte-microglia co-culture model of inflammation. Primary rat astrocytes co-cultures containing 5%-10% (M5, \"physiological\" conditions) or 30%-40% (M30, \"pathological inflammatory\" conditions) of microglia were treated with different concentrations of BRV (0.5, 2, 10, and 20 μg/ml) for 24 h. Glial cell viability was measured by MTT assay. Microglial act","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2025-04-21T14:13:02.858Z","creation":"2025-04-21T14:13:02.858Z"},"accession":"S-EPMC9670320","cross_references":{"pubmed":["36406753"],"doi":["10.3389/fncel.2022.995861"]}}